Patients with VEXAS Diagnosed in a Danish Tertiary Rheumatology Setting Have Highly Elevated Inflammatory Markers, Macrocytic Anaemia and Negative Autoimmune Biomarkers

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2024 Jul 5

PMID 38967099

Authors

Mads Nyhuus Bendix Rasch

Fruzsina Szabados

Jens Magnus Bernth Jensen

Kirstine Overgaard Nielsen

Ellen-Margrethe Hauge

Anne Troldborg

Affiliations

Soon will be listed here.

Abstract

Background: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) is an autoinflammatory condition with overlapping features of rheumatology and haematology caused by somatic mutations in the UBA1 gene. Patients present with highly variable symptoms and their path towards diagnosis are often complicated and characterised by extensive examinations. It is, therefore, pivotal that clinicians become familiar with the clinical presentation of VEXAS to advance identification of patients with the disease.

Objectives: We aimed to (1) characterise patients diagnosed with VEXAS in a tertiary rheumatology referral centre, (2) identify common rheumatological biomarkers that may distinguish VEXAS from other rheumatic diseases and (3) suggest which clinical findings should motivate genetic testing for VEXAS.

Methods: Patients were identified and diagnosed at the department of Rheumatology, Aarhus University Hospital (AUH), Denmark. Blood samples were examined for VEXAS-associated variants by Sanger sequencing at the department of Clinical Immunology, AUH. Clinical and biochemical data were retrieved from the hospital electronic patient chart.

Results: Eleven male patients with clinical suspicion of VEXAS underwent sequencing. Five of these carried known VEXAS-associated variants. Median age at diagnosis was 84 (75-87) years. All patients had significantly elevated inflammatory markers with a median C-reactive protein (CRP) of 297 (196-386) mg/L and macrocytic anaemia. None of the patients presented common biomarkers for autoimmunity.

Conclusion: Danish patients with VEXAS syndrome are men with persistent inflammation, constitutional symptoms and heterogeneous clinical presentations. Shared features for all patients in this study were highly elevated inflammatory markers, macrocytic anaemia and negative autoimmune biomarkers.

References

Koster M, Kourelis T, Reichard K, Kermani T, Beck D, Ospina Cardona D . Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. Mayo Clin Proc. 2021; 96(10):2653-2659. DOI: 10.1016/j.mayocp.2021.06.006. View

Ferrada M, Sikora K, Luo Y, Wells K, Patel B, Groarke E . Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis Rheumatol. 2021; 73(10):1886-1895. DOI: 10.1002/art.41743. View

Bourbon E, Heiblig M, Valentin M, Barba T, Durel C, Lega J . Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood. 2021; 137(26):3682-3684. DOI: 10.1182/blood.2020010177. View

Milholland B, Auton A, Suh Y, Vijg J . Age-related somatic mutations in the cancer genome. Oncotarget. 2015; 6(28):24627-35. PMC: 4694783. DOI: 10.18632/oncotarget.5685. View

Obiorah I, Patel B, Groarke E, Wang W, Trick M, Ombrello A . Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv. 2021; 5(16):3203-3215. PMC: 8405186. DOI: 10.1182/bloodadvances.2021004976. View

Heiblig M, Patel B, Groarke E, Bourbon E, Sujobert P . Toward a pathophysiology inspired treatment of VEXAS syndrome. Semin Hematol. 2021; 58(4):239-246. DOI: 10.1053/j.seminhematol.2021.09.001. View

Machiela M, Zhou W, Karlins E, Sampson J, Freedman N, Yang Q . Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nat Commun. 2016; 7:11843. PMC: 4909985. DOI: 10.1038/ncomms11843. View

Carrel L, Clemson C, Dunn J, Miller A, Hunt P, Lawrence J . X inactivation analysis and DNA methylation studies of the ubiquitin activating enzyme E1 and PCTAIRE-1 genes in human and mouse. Hum Mol Genet. 1996; 5(3):391-401. DOI: 10.1093/hmg/5.3.391. View

Poulter J, Collins J, Cargo C, De Tute R, Evans P, Ospina Cardona D . Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood. 2021; 137(26):3676-3681. PMC: 8462400. DOI: 10.1182/blood.2020010286. View

10.

Loschi M, Roux C, Sudaka I, Ferrero-Vacher C, Marceau-Renaut A, Duployez N . Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. Bone Marrow Transplant. 2022; 57(2):315-318. DOI: 10.1038/s41409-021-01544-y. View

11.

Beck D, Ferrada M, Sikora K, Ombrello A, Collins J, Pei W . Somatic Mutations in and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2020; 383(27):2628-2638. PMC: 7847551. DOI: 10.1056/NEJMoa2026834. View

12.

Georgin-Lavialle S, Terrier B, Guedon A, Heiblig M, Comont T, Lazaro E . Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2021; 186(3):564-574. DOI: 10.1111/bjd.20805. View

13.

Stubbins R, McGinnis E, Johal B, Chen L, Wilson L, Ospina Cardona D . VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome). Haematologica. 2021; 107(4):1011-1013. PMC: 8968888. DOI: 10.3324/haematol.2021.280238. View

14.

Glickman M, Ciechanover A . The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002; 82(2):373-428. DOI: 10.1152/physrev.00027.2001. View

15.

Barba T, Jamilloux Y, Durel C, Bourbon E, Mestrallet F, Sujobert P . VEXAS syndrome in a woman. Rheumatology (Oxford). 2021; 60(11):e402-e403. DOI: 10.1093/rheumatology/keab392. View

16.

Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L . Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv. 2021; 6(3):998-1003. PMC: 8945317. DOI: 10.1182/bloodadvances.2021004749. View

17.

Arlet J, Terrier B, Kosmider O . Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2021; 384(22):2163. DOI: 10.1056/NEJMc2102124. View

18.

Navid F, Colbert R . Causes and consequences of endoplasmic reticulum stress in rheumatic disease. Nat Rev Rheumatol. 2016; 13(1):25-40. DOI: 10.1038/nrrheum.2016.192. View

19.

Tsuchida N, Kunishita Y, Uchiyama Y, Kirino Y, Enaka M, Yamaguchi Y . Pathogenic variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. 2021; 80(8):1057-1061. DOI: 10.1136/annrheumdis-2021-220089. View

20.

Muratore F, Marvisi C, Castrignano P, Nicoli D, Farnetti E, Bonanno O . VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis. Arthritis Rheumatol. 2021; 74(4):665-670. PMC: 8957507. DOI: 10.1002/art.41992. View